{"disease":{"id":"digestive-tumor","name":"digestive tumor"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05038254","title":"Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03375320","title":"Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":298,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01841736","title":"Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":171,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05260385","title":"To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":133,"lead_sponsor_name":"Beijing Konruns Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05773274","title":"Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07053150","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT04505553","title":"Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT04993261","title":"An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":71,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04611711","title":"Phase I/II Clinical Study of Decitabine Combined With TQB2450 Injection or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT05139082","title":"Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT04615312","title":"A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT03950609","title":"Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04234568","title":"Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":31,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02909452","title":"Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":false},{"nct_id":"NCT02897778","title":"Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":false},{"nct_id":"NCT05673434","title":"A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1-positive Tumors of Digestive System","phase":"NA","overall_status":"UNKNOWN","enrollment_count":24,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT02420691","title":"Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT05946226","title":"A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"Suzhou Immunofoco Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT07150546","title":"Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT06016855","title":"Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"Vanderbilt-Ingram Cancer Center","has_results":false}],"total":21},"guidelines":[],"source":"Drug Landscape verified database"}